{
    "N/R/U": null,
    "Applicant": "Janssen Biotech, Inc.",
    "BLA Number": "125746",
    "Proprietary Name": "Carvykti",
    "Proper Name": "ciltacabtagene autoleucel",
    "BLA Type": "351(a)",
    "Strength": "0.5 to 1.0x10^6 chimeric antigen receptor (CAR)-positive viable T cells per kg of body weight, with a maximum dose of 1x10^8 CAR-positive viable T cells in one infusion",
    "Dosage Form": "For Injection",
    "Route of Administration": "Intravenous",
    "Product Presentation": "Bag",
    "Marketing Status": "Rx",
    "Licensure": "Licensed",
    "Approval Date": "February 28, 2022",
    "Ref. Product Proper Name": null,
    "Ref. Product Proprietary Name": null,
    "Supplement Number": "0",
    "Submission Type": "Original",
    "License Number": "1864",
    "Product Number": "001",
    "Center": "CBER",
    "Date of First Licensure": "February 28, 2022",
    "Exclusivity Expiration Date": null,
    "First Interchangeable Exclusivity Exp. Date": null,
    "Ref. Product Exclusivity Exp. Date": "February 28, 2034",
    "Orphan Exclusivity Exp. Date": "April 05, 2031"
}